0001144204-15-027693.txt : 20150505 0001144204-15-027693.hdr.sgml : 20150505 20150505170648 ACCESSION NUMBER: 0001144204-15-027693 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150501 FILED AS OF DATE: 20150505 DATE AS OF CHANGE: 20150505 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5600 BLAZER PARKWAY STREET 2: SUITE 200 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 5600 BLAZER PARKWAY STREET 2: SUITE 200 CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: NEOPROBE CORP DATE OF NAME CHANGE: 19940714 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LARSON BRENT L CENTRAL INDEX KEY: 0001195766 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35076 FILM NUMBER: 15833928 MAIL ADDRESS: STREET 1: 425 METRO PLACE NORTH STREET 2: STE 400 CITY: DUBLIN STATE: OH ZIP: 43017 4 1 form474300_20150505050629-.xml X0306 4 2015-05-01 0 0000810509 NAVIDEA BIOPHARMACEUTICALS, INC. NAVB 0001195766 LARSON BRENT L 5600 BLAZER PARKWAY, SUITE 200 DUBLIN OH US 43017 0 1 0 0 EVP, CFO, Treas and Sec'y Common Stock 2015-05-01 4 S 0 12500 1.33 D 309737 D Sales effected pursuant to a 10b5-1 trading plan adopted by Mr. Larson on March 13, 2015 Weighted average of sales prices ranging from $1.31 to $1.35 per share. Mr. Larson undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. William J. Kelly, attorney-in-fact 2015-05-05